![logo](/logos/ONTX.webp)
Onconova Therapeutics, Inc.
NASDAQ:ONTX
0.89 (USD) • At close April 2, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Onconova Therapeutics, Inc. |
Symbool | ONTX |
Munteenheid | USD |
Prijs | 0.995 |
Beurswaarde | 20,904,684 |
Dividendpercentage | 0% |
52-weken bereik | 0.551 - 1.45 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Steven M. Fruchtman M.D. |
Website | https://www.onconova.com |
An error occurred while fetching data.
Over Onconova Therapeutics, Inc.
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)